Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis
Objective: to assess the economic outcomes of using anidulafungin (Eraxis®) in comparison with the recommended treatment regimens in adult patients with invasive candidiasis.Materials and methods. The economic impact assessment was carried out using “cost–effectiveness” analysis and “budget impact”...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-10-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/375 |
| _version_ | 1797855545798950912 |
|---|---|
| author | S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova |
| author_facet | S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova |
| author_sort | S. V. Nedogoda |
| collection | DOAJ |
| description | Objective: to assess the economic outcomes of using anidulafungin (Eraxis®) in comparison with the recommended treatment regimens in adult patients with invasive candidiasis.Materials and methods. The economic impact assessment was carried out using “cost–effectiveness” analysis and “budget impact” analysis. “Cost–effectiveness” and “budget impact” analyses were performed in Microsoft Excel model.Results. An analysis of the effectiveness showed that the use of anidulafungin is characterized by higher survival (79.25 % vs 66.17 % for caspofungin and 60.84 % for mikafungin). The cost of anidulafungin was 377.7 thousand rubles, which is comparable with the course of caspofungin and 61 % lower than the cost of micafungin therapy. “Cost–effectiveness” analysis showed that the use of the anidulafungin in the treatment of invasive candidiasis is pharmacoeconomically effective and has a “cost–effectiveness” ratio comparable to caspofungin in terms of the effectiveness of therapy for 7 days and exceeds it in terms of the cost of preserving the patient»s life by 14.5 %. Compared to micafungin, anidulafungin is both more economical and more effective in terms of preserving the patient's life, reaching an advantage of up to 45 %. An analysis of the impact on the budget showed that with the complete replacement of the currently used treatment regimens in the target population of 11,840 patients with invasive candidiasis with anidulafungin, it is possible to reduce the burden on the budget of the healthcare system to 17 % or 1458.6 million rubles in year. The average savings in the 3‑year study horizon, taking into account the gradual switching of 25, 50 and 75 % of the target patient population, amounted to 1277.9 million rubles per year or 14.4 %. A sensitivity analysis confirmed the results.Conclusion. Based on results, it can be concluded that the use of the drug anidulafungin (Eraxis®) in patients with invasive candidiasis is economically the preferred option compared to the use of current antibiotic therapy regimens. |
| first_indexed | 2024-04-09T20:24:21Z |
| format | Article |
| id | doaj.art-7b2522998129482ba55cb4761f241f56 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:24:21Z |
| publishDate | 2019-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-7b2522998129482ba55cb4761f241f562023-03-30T20:15:12ZrusABV-pressОнкогематология1818-83462413-40232019-10-011439810810.17650/1818-8346-2019-14-3-98-108324Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasisS. V. Nedogoda0A. S. Salasyuk1I. N. Barykina2V. O. Smirnova3Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityObjective: to assess the economic outcomes of using anidulafungin (Eraxis®) in comparison with the recommended treatment regimens in adult patients with invasive candidiasis.Materials and methods. The economic impact assessment was carried out using “cost–effectiveness” analysis and “budget impact” analysis. “Cost–effectiveness” and “budget impact” analyses were performed in Microsoft Excel model.Results. An analysis of the effectiveness showed that the use of anidulafungin is characterized by higher survival (79.25 % vs 66.17 % for caspofungin and 60.84 % for mikafungin). The cost of anidulafungin was 377.7 thousand rubles, which is comparable with the course of caspofungin and 61 % lower than the cost of micafungin therapy. “Cost–effectiveness” analysis showed that the use of the anidulafungin in the treatment of invasive candidiasis is pharmacoeconomically effective and has a “cost–effectiveness” ratio comparable to caspofungin in terms of the effectiveness of therapy for 7 days and exceeds it in terms of the cost of preserving the patient»s life by 14.5 %. Compared to micafungin, anidulafungin is both more economical and more effective in terms of preserving the patient's life, reaching an advantage of up to 45 %. An analysis of the impact on the budget showed that with the complete replacement of the currently used treatment regimens in the target population of 11,840 patients with invasive candidiasis with anidulafungin, it is possible to reduce the burden on the budget of the healthcare system to 17 % or 1458.6 million rubles in year. The average savings in the 3‑year study horizon, taking into account the gradual switching of 25, 50 and 75 % of the target patient population, amounted to 1277.9 million rubles per year or 14.4 %. A sensitivity analysis confirmed the results.Conclusion. Based on results, it can be concluded that the use of the drug anidulafungin (Eraxis®) in patients with invasive candidiasis is economically the preferred option compared to the use of current antibiotic therapy regimens.https://oncohematology.abvpress.ru/ongm/article/view/375candidiasisinvasive candidiasisanidulafungincaspofunginmicafungin“budget impact” analysis“cost–effectiveness” analysis |
| spellingShingle | S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis Онкогематология candidiasis invasive candidiasis anidulafungin caspofungin micafungin “budget impact” analysis “cost–effectiveness” analysis |
| title | Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis |
| title_full | Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis |
| title_fullStr | Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis |
| title_full_unstemmed | Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis |
| title_short | Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis |
| title_sort | pharmacoeconomic analysis of the anidulafungin eraxisr in adult patients with invasive candidiasis |
| topic | candidiasis invasive candidiasis anidulafungin caspofungin micafungin “budget impact” analysis “cost–effectiveness” analysis |
| url | https://oncohematology.abvpress.ru/ongm/article/view/375 |
| work_keys_str_mv | AT svnedogoda pharmacoeconomicanalysisoftheanidulafungineraxisrinadultpatientswithinvasivecandidiasis AT assalasyuk pharmacoeconomicanalysisoftheanidulafungineraxisrinadultpatientswithinvasivecandidiasis AT inbarykina pharmacoeconomicanalysisoftheanidulafungineraxisrinadultpatientswithinvasivecandidiasis AT vosmirnova pharmacoeconomicanalysisoftheanidulafungineraxisrinadultpatientswithinvasivecandidiasis |